Catalyst is a venture capital firm investing in disruptive solutions for global, unmet healthcare needs.
Investing in breakthrough medical devices: A short video story
In addition to providing exceptional returns for our investors, Catalyst Health Ventures invests in companies that will improve patient outcomes and potentially save lives. Below is a video on a medical device called the AngioVac, a device that removes undesirable intravascular material such as blood clots and pulmonary embolisms from the venous system. This was a Catalyst funded company which was then acquired by AngioDynamics in 2012. The following video demonstrates the importance of investing in breakthrough medical device technologies and how that translates into saving patients lives.
A 32 Year Old’s Startup, Inspired by a Health Scare, Sells for $275 million
We are pleased to inform you that Catalyst Health Ventures Portfolio company nVision Medical has been acquired by Marlborough, MA based Boston Scientific Corporation (NYSE: BSX) for a total potential cash consideration of up to $275M. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Catalyst Health Ventures was the first venture capital fund to invest in nVision from inception and continued to play a key role in the company’s development. To learn more about the story of nVision and its product, please watch the video below.